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Background: Pts with severe aortic stenosis at extreme risk for surgery can have balloon aortic valvuloplasty (BAV) for treatment of symptoms, 
or as a temporizing step prior to transcatheter aortic valve replacement. However, post-procedural complications such as bleeding, vascular 
complications and stroke are common. The predictors of adverse outcomes post BAV are not known.
Methods: We examined the in-hospital outcomes of pts who underwent non-emergent, retrograde BAV from January 2005 to July 2011 with 
heparin (UFH) or bivalirudin as procedural antithrombin. Net adverse clinical events (NACE) were a composite of mortality, myocardial infarction, 
stroke and Bleeding Academic Research Consortium type ≥3 bleeding. All events were adjudicated by an independent CEC who were blinded to the 
antithrombin used.
Results: Of 428 patients, 205 (48%) had UFH and 223 (52%) had bivalirudin. “Preclosure technique” for closure of the BAV access site was 
attempted in 245 pts (57%). The mean age was 83 ± 9, 45% were male, and 18% were considered frail*. The mean logistic Euroscore was 22.1%. 66 
pts (31.2%) had an adverse event post BAV. The figure shows the independent predictors of NACE.
Conclusion: In this large review of BAV in elderly, high risk pts, frailty and the Euroscore were significant predictors of poor outcomes with 
increased rates of NACE. Access preclosure was independently associated with a reduction in NACE, and bivalirudin approached significance with 
respect to reduced NACE.
 
